PolySciTech products used for aerosol delivery

PolySciTech (www.polyscitech.com) provides a wide array of biodegradable polymers including Mal-PEG-PLGA. Recently this polymer was utilized to generate STL labelled nanoparticles for aerosol delivery across the blood-brain-barrier. Read more: Justin E. Piazza, Chao Zhu, Ravi Selvaganapathy, Todd Hoare, Saransh B. Jain, Farhat Hossain and Ram K. Mishra “The Use of a Novel Intranasal Spray Device for the Administration of Nanoparticles for the Treatment of Rodents” ASME. J. Med. Devices. 2015;():. doi:10.1115/1.4029907 http://medicaldevices.asmedigitalcollection.asme.org/article.aspx?articleid=2174069

“Abstract: Experimental intranasal delivery of nanoparticle drug carriers is typically performed using a pipette with or without anaesthesia, a technique that may be a poor simulation of practical intranasal administration of drug-loaded nanoparticles in humans. Existing intranasal spray devices suffer from drawbacks in terms of variability in dose-control and spray duration as well as the application of non-uniform pressure fields when a nanoparticle-formulated drug is aerosolized. Furthermore, existing spray devices require large volumes that may not be available or may be prohibitively expensive to prepare. In response, we have developed a novel pneumatically-driven intranasal spray device for the administration of nanoparticles that is capable of administering extremely small quantities (50-100 µL) of nanoparticle suspension in a fine spray that disperses the nanoparticles uniformly on to the tissue. This device was validated using haloperidol-loaded Solanum tuberosum lectin (STL)-functionalized, poly(ethylene glycol)-block-poly(D,L-lactic-co-glycolic acid) (PEG-PLGA) nanoparticles targeted for delivery to the brain for schizophrenia treatment. A pneumatic pressure of 100 kPa was found to be optimal to produce a spray that effectively aerosolizes nanoparticle suspensions and delivers them evenly to the olfactory epithelium. Intranasal administration of STL-functionalized nanoparticles using the intranasal spray device increased brain tissue haloperidol concentrations by a factor of 1.2-1.5x compared to STL-functionalized nanoparticles administered intranasally with a pipette. Such improved delivery enables the use of lower drug doses and thus offers both fewer side-effects and lower costs without compromising therapeutic efficacy.”